IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. William Ho, CEO and co-founder of IN8bio, will be presenting in a fireside chat format on Monday, September 9, 2024, at 2:30 p.m. ET.
The presentation will be accessible via a live webcast, with a replay option available afterwards. Interested parties can find the webcast under the "Events and Presentations" section of the IN8bio website at https://investors.in8bio.com. This event provides an opportunity for investors and analysts to gain insights into IN8bio's innovative approach to cancer treatment using gamma-delta T cell therapies.
IN8bio, un'azienda biofarmaceutica in fase clinica specializzata in terapie con cellule T gamma-delta, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. William Ho, CEO e cofondatore di IN8bio, presenterà in un formato di chiacchierata informale lunedì 9 settembre 2024, alle 14:30 ET.
La presentazione sarà accessibile tramite un webcast dal vivo, con la possibilità di rivederla successivamente. Gli interessati possono trovare il webcast sotto la sezione
- None.
- None.
NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:
H.C. Wainwright 26th Annual Global Investment Conference
Format Fireside Chat
Date/Time Monday, September 9, 2024, at 2:30 p.m. ET.
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH
IN8bio, Inc.
203.494.7411
gdschulman@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for IN8bio at the H.C. Wainwright conference?
What is the format of IN8bio's presentation at the H.C. Wainwright conference?
How can I access IN8bio's presentation at the H.C. Wainwright conference?
What is IN8bio's focus in biopharmaceutical research?
